Trial Profile
A second phase III trial of olmutinib (BI 1482694) for the treatment of non-small cell lung cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Olmutinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Jun 2016 New trial record
- 05 Jun 2016 According to a Boehringer Ingelheim media release, this is one of the two phase III trials expected to be initiated in 2016.